A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three ...

Pilot trial of lithium treatment in mild cognitive impairment shows modest memory effects, informing larger confirmatory ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral ...

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition ...

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study Adult female BCS exposed to ≥4 cycles of adjuvant ...

Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...

Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2 clinical trial in patients with cognitive impairment associated ...

Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort move toward normal aging profiles across validated clinical scales, supporting its relevance in early-stage ...

Multiple healthy diets, especially the Dietary Approaches to Stop Hypertension-style diet, were tied to better cognitive function and a lower risk for cognitive decline, a study in JAMA Neurology ...

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), ...